Research map: Glucocorticoid tapering and clinical outcomes during belimumab treatment in systemic lupus erythematosus: a retrospective real-world cohort study with exploratory renal analyses

Back to the article

Papers in this map

  1. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics · Yoshinobu Kanda · 2012 · 19329 citations · Cited by this paper
  2. Digital interactions with the pharmaceutical industry: a qualitative focus group study on the perspectives of rheumatology care providers in Germany · 2026 · Related
  3. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus · M.C. Hochberg · 1997 · 11598 citations · Cited by this paper
  4. Effects of a cow’s milk protein–free diet as an adjunct to standard therapy in juvenile idiopathic arthritis: a randomized controlled study · 2026 · Related
  5. Systemic Lupus Erythematosus · George C. Tsokos · 2011 · 2776 citations · Cited by this paper
  6. Short-course prednisone and methotrexate in a cohort of patients with polymyalgia rheumatica: a potential therapeutic approach · 2026 · Related
  7. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial · Sandra Navarra · 2011 · 2099 citations · Cited by this paper
  8. Add-on iguratimod or tacrolimus in methotrexate in patients with rheumatoid arthritis not achieving remission with methotrexate: a retrospective propensity score-matched study · 2025 · Related
  9. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited · Jan J. Weening · 2004 · 2020 citations · Cited by this paper
  10. Real-world effectiveness and safety of upadacitinib in Japanese patients with rheumatoid arthritis: impact of age, renal function, and low-dose therapy · 2026 · Related
  11. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus · Richard Alan Furie · 2011 · 1694 citations · Cited by this paper
  12. Population-specific antiphospholipid antibody titres in a South Indian cohort: defining cut-off values and implications for diagnosis from a cross-sectional validation study · 2026 · Related
  13. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices · Ingeborg M. Bajema · 2018 · 1071 citations · Cited by this paper
  14. “What do you want this information for?”: cognitive interviews with arthritis researchers to inform the development of a health equity-focused demographic survey for outcomes research · 2026 · Related
  15. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update · Antonis Fanouriakis · 2023 · 1063 citations · Cited by this paper
  16. Longitudinal clinical and musculoskeletal ultrasound assessment after switching from oral to subcutaneous methotrexate in rheumatoid arthritis: a two-center real-world study · 2026 · Related
  17. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis · Richard Alan Furie · 2020 · 1036 citations · Cited by this paper
  18. Self-reported depression on the Lupus Impact Tracker questionnaire (LIT) is associated with glucocorticoid use and fibromyalgia in systemic lupus erythematosus, according to RELESSER-PROS registry data · 2026 · Related
  19. Lupus nephritis · Hans‐Joachim Anders · 2020 · 972 citations · Cited by this paper
  20. Update on Lupus Nephritis · Salem J. Almaani · 2016 · 953 citations · Cited by this paper
  21. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force · Ronald van Vollenhoven · 2014 · 743 citations · Cited by this paper
  22. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring · Christine Hsieh · 2011 · 331 citations · Cited by this paper
  23. Prednisone, Lupus Activity, and Permanent Organ Damage · Mae Thamer · 2009 · 235 citations · Cited by this paper
  24. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis · Brad H. Rovin · 2021 · 214 citations · Cited by this paper
  25. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus · Luca Iaccarino · 2016 · 140 citations · Cited by this paper
  26. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study · Zahi Touma · 2017 · 79 citations · Cited by this paper
  27. The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future · Samir V. Parikh · 2015 · 70 citations · Cited by this paper
  28. Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes · April M Jorge · 2024 · 45 citations · Cited by this paper
  29. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks · Binod Neupane · 2023 · 28 citations · Cited by this paper
  30. Lupus Nephritis: The Significant Contribution of Electron Microscopy · Luan D. Truong · 2021 · 16 citations · Cited by this paper
  31. Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus · Yoko Wada · 2017 · 11 citations · Cited by this paper
  32. The importance of tubuloreticular inclusions in lupus nephritis · Johannes Cornelis Nossent · 2019 · 7 citations · Cited by this paper
  33. Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study) · Marie Jaïs · 2024 · 7 citations · Cited by this paper
  34. An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosus · Atsushi Manabe · 2024 · 6 citations · Cited by this paper
  35. Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry · Paola Vidal-Montal · 2026 · 5 citations · Cited by this paper
  36. Administration of belimumab prior to standard immunosuppression in patients with early active lupus hinders accrual of new EULAR/ACR criteria within the first 12 months of treatment · Mariele Gatto · 2025 · 2 citations · Cited by this paper
  37. Efficacy and safety of belimumab in lupus nephritis: a real-world retrospective observational study stratified by treatment phase and age · Shuting Hou · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)